the product in the database has an inactive status
indications:
Active duodenal ulcer. Active gentle gastric ulcer. Gastroesophageal reflux with erosions or ulcers. Long-term treatment of gastro-oesophageal reflux. The drug can be used temporarily (on demand) in the case of complaints associated with gastro-oesophageal reflux. Peptic ulcer of the stomach or duodenum coexisting with infectionHelicobacter pylori.
Composition:
1 tabl enterally contains 10 mg or 20 mg of Rabeprazole sodium.
Action:
A drug that inhibits gastric secretion from the group of benzimidazoles. It inhibits the secretion of hydrochloric acid in the stomach by specific inhibition of H+/ K+-ATP-azy (proton pump) on the secretory surface of gastric parietal cells. This inhibition is dose-dependent and applies to both basal and stimulated secretion of hydrochloric acid, regardless of the stimulus. Rabeprazole has no anticholinergic activity or antagonistic properties against the H receptor2. After an oral dose of 20 mg, the onset of action occurs within an hour. The maximum effect occurs within 2-4 h. Rabeprazole is approximately 97% bound to plasma proteins. About 90% of the dose is excreted in the urine, the remainder in the faeces.
Contraindications:
Hypersensitivity to Rabeprazole sodium, benzimidazoles or other ingredients. Pregnancy and breastfeeding.
Precautions:
In patients with severe hepatic insufficiency, extreme caution is recommended at the beginning of treatment. Use in children is not recommended - no experience regarding the use of the drug in this age group.
Pregnancy and lactation:
The use of the drug is contraindicated.
Side effects:
The observed adverse reactions were generally mild or moderate and transient. The use of rabeprazole was associated with: headache and dizziness, diarrhea, nausea (> 5%), rhinitis, abdominal pain, weakness, flatulence, sore throat, vomiting, unspecific pain or backache, flu-like symptoms, infection , cough, constipation, insomnia (2-5%), skin rash, muscle pain, chest pain, dry mouth, indigestion, nervousness, drowsiness, bronchitis, sinusitis, chills, leg cramps, urinary tract infections, joint pain, fever (<2%). However, only headache, diarrhea, abdominal pain, weakness, flatulence, skin rash and dry mouth were associated with the use of the preparation. An increase in liver enzymes has been reported.
Dosage:
Orally, adults. Active duodenal ulcer and active gentle gastric ulcer: 20 mg once a day. Cure of the active duodenal ulcer usually occurs within 4 weeks, if necessary, the treatment can be extended for another 4 weeks. Active gastric ulcer is treated within 6 weeks, if necessary, treatment can be extended for another 6 weeks. Gastroesophageal reflux with occurrence of erosions or ulcers: 20 mg once a day for 4-8 weeks. Long-term treatment of gastro-oesophageal reflux: the maintenance dose is 10-20 mg once a day depending on the patient's response. Emergency (on-demand) treatment in the event of complaints associated with gastro-oesophageal reflux in patients without oesophagitis: 10 mg once a day. InfectionH. pylori - eradication therapy: the recommended dosage regimen is 20 mg rabeprazole twice daily + 500 mg Clarithromycin twice daily + 1 g Amoxicillin twice daily for 7 days. The preparation should be taken in the morning, before breakfast, the tablets should be swallowed whole.
(C)
